The case
A 59-y-old married man presented to his physician in 1995 with dysuria and other symptoms that were attributed to a urinary tract infection. The symptoms continued over 2 y, despite antibiotic treatment. In 1997, the patient approached a urologist for a second opinion, and his prostate-specific antigen (PSA) level was 9.8 ng/ ml. Transrectal biopsy confirmed a diagnosis of clinically localized prostate cancer (cT2, Gleason score 9 (4 þ 5), 4/ 8 cores affected). After discussion of the treatment options (radical prostatectomy, brachytherapy, and external-beam radiotherapy), the patient opted to undergo surgery. Histopathologic restaging revealed extensive disease within the prostate, with positive surgical margins (pT3). Postoperatively, the PSA level remained at 40.5 ng/ml, and within 3 months started to rise. Upon second-line radiotherapy (70 Gy over 6 weeks), preceded by a 3-month depot injection of goserelin ('Zoladex'), the PSA level was stable for 2 y at o0.2 ng/ml before rising again. When the PSA level reached 41 ng/ml, hormonal therapy was discussed; the patient elected to receive monotherapy with the nonsteroidal antiandrogen bicalutamide ('Casodex') 150 mg to avoid the side effects of castration. Within 3 months, the PSA level fell to 0.1 ng/ ml; however, after 2 y of bicalutamide treatment, the patient decided to discontinue therapy after developing gynecomastia, which he found embarrassing. Subsequently, the PSA level gradually increased to 23 ng/ml and, in May 2004, the patient developed breathlessness and hemoptysis. A computed tomography scan and bone scan revealed pulmonary metastases, but no bone and other soft tissue metastases. A lung biopsy revealed moderately differentiated metastatic adenocarcinoma. The patient still wished to avoid castration, and elected to restart bicalutamide 150 mg monotherapy. By December 2004, the PSA level had fallen to 2.7 ng/ml and there was marked regression of the pulmonary metastases (Figures 1a and b) . This partial response is maintained at the time of writing.
Discussion
Risk of metastatic progression to advanced prostate cancer Although the outcome following radical prostatectomy is generally favorable, up to one-third of men will experience PSA progression within 10 y. For men whose postoperative PSA level remains at 40.4 ng/ml, as in this case, the PSA progression rate approaches 100%. 1 Such patients are at increased risk of developing metastases 2 and should be considered for second-line radiotherapy and/or hormonal therapy.
Prostate cancer metastases are most commonly skeletal; pulmonary metastases are usually only seen after bone or lymph node involvement. 3 The present case, in which pulmonary metastases developed without detectable disease in the bones or other soft tissue sites, is very rare.
Recent guidelines on hormonal therapy for advanced prostate cancer
The mainstay of treatment for men with advanced prostate cancer is hormonal therapy. Recent American Society of Clinical Oncology (ASCO) guidelines 4 recommended bilateral orchiectomy or medical castration with an LH-RH agonist as initial treatments. Nonsteroidal antiandrogen monotherapy may be discussed as an alternative to castration. Steroidal antiandrogens should not be offered as monotherapy, since they have a smaller time to disease progression relative to LH-RH agonists. Combination therapy, that is, castration combined with a nonsteroidal antiandrogen, is a further treatment option.
Treatment choice: balancing efficacy and acceptable side effects
Central to the choice of hormonal therapy is striking a balance between efficacy and acceptable side effects. After an assessment of disease risk, patients should be informed about the benefits and side effects of all options. 4 Bilateral orchiectomy is a simple and cost-effective procedure, but is nonreversible and can carry a significant psychologic burden. Two large randomized trials demonstrated that the LH-RH agonist goserelin is as effective as orchiectomy in terms of survival in patients with metastatic disease. 5 Moreover, LH-RH agonists are potentially reversible, improve quality of life compared with orchiectomy, and are often preferred by patients. 6 Both surgical and medical castration are associated with side effects that commonly include decreased libido, sexual dysfunction, fatigue, loss of bone mineral density and muscle mass, and osteoporotic fractures.
This patient wished to avoid the side effects of castration, and opted to receive bicalutamide 150 mg monotherapy. Nonsteroidal antiandrogens have an improved side-effect profile compared with castrationbased therapy, particularly in terms of maintaining sexual interest and physical capacity and avoiding loss of bone mineral density. 7, 8 However, these benefits in favor of nonsteroidal antiandrogen monotherapy need to be balanced against the available comparative efficacy data from randomized trials in patients with metastatic disease, which show mixed results. 9 It should be noted that there are currently no randomized trial data on the use of any hormonal therapies in patients with rising PSA.
Among the nonsteroidal antiandrogens, bicalutamide 150 mg offers an attractive monotherapy option in terms of its risk of side effects, with a low incidence of nonpharmacologic complications. 10 In contrast, flutamide carries a higher risk of gastrointestinal effects and hepatotoxicity than the other nonsteroidal antiandrogens, and nilutamide is associated with delayed adaptation to darkness, alcohol intolerance, and interstitial pneumonitis. With all nonsteroidal antiandrogens, the most frequent side effects are mild-to-moderate gynecomastia and breast pain. 10 Patients should be made aware that management options are available for these conditions, including prophylactic and therapeutic radiotherapy and tamoxifen.
While combination therapy is a further option for advanced disease, [11] [12] [13] since castration is incorporated, this strategy was not suitable for this patient. An overall survival benefit of combination therapy using flutamide or nilutamide as the nonsteroidal antiandrogen relative to castration alone was revealed in a meta-analysis conducted by the Prostate Cancer Trialists' Collaborative Group. 11 Klotz et al 12 also recently determined a high probability (98.5%) that combination therapy using bicalutamide 50 mg provides an estimated 20% reduction in the risk of death vs castration alone.
Future treatment considerations
When bone metastases are present, median survival is only approximately 3.0-3.5 y. Data in patients with pulmonary metastases but without detectable bone metastases are limited, but case study evidence indicates that such patients experience a dramatic and often complete response to hormonal therapy, as well as long-term survival. 3 Although this patient is responding well to bicalutamide 150 mg, patients treated with hormonal therapy for metastatic disease often experience PSA progression. Many progressors respond to withdrawal of the hormonal therapy, or to a different hormonal therapy. For patients who experience PSA progression on antiandrogen monotherapy, castrationbased therapy should be considered standard.
14 Indeed, data from the bicalutamide Early Prostate Cancer program show that second-line hormonal therapy (mostly castration based) produces a PSA response in approximately 55% of patients who progress on bicalutamide 150 mg monotherapy.
Once there is no response to further hormonal manipulation, only then is the tumor truly hormone refractory. Taxane-based chemotherapy has recently been 
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shown to prolong survival in hormone-refractory prostate cancer 15 and, if the patient can tolerate aggressive treatment, this treatment should be considered when the PSA level starts rising in spite of androgen ablation therapy.
Conclusions
Patients who fail to achieve an undetectable PSA level following radical prostatectomy are at considerable risk of disease progression and should be considered for second-line radiotherapy and/or hormonal therapy. While skeletal metastases are most common, pulmonary metastases are not uncommon in patients with advanced prostate cancer, though they usually develop after disease spread to the bones or lymph nodes. The mainstay of treatment for advanced prostate cancer is hormonal therapy and options include surgical or medical castration, nonsteroidal antiandrogen monotherapy, and combination therapy. In this case, the patient assessed the potential quality-of-life benefits of bicalutamide 150 mg monotherapy vs the potential lower efficacy relative to castration-based therapy, and decided that the quality-of-life benefits were most important.
